PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of frontimmuLink to Publisher's site
 
Front Immunol. 2017; 8: 238.
Published online 2017 March 6. doi:  10.3389/fimmu.2017.00238
PMCID: PMC5337509

Epitope-Specific Suppression of IgG Responses by Passively Administered Specific IgG: Evidence of Epitope Masking

Abstract

Specific IgG, passively administered together with particulate antigen, can completely prevent induction of antibody responses to this antigen. The ability of IgG to suppress antibody responses to sheep red blood cells (SRBCs) is intact in mice lacking FcγRs, complement factor 1q, C3, or complement receptors 1 and 2, suggesting that Fc-dependent effector functions are not involved. Two of the most widely discussed explanations for the suppressive effect are increased clearance of IgG–antigen complexes and/or that IgG “hides” the antigen from recognition by specific B cells, so-called epitope masking. The majority of data on how IgG induces suppression was obtained through studies of the effects on IgM-secreting single spleen cells during the first week after immunization. Here, we show that IgG also suppresses antigen-specific extrafollicular antibody-secreting cells, germinal center B-cells, long-lived plasma cells, long-term IgG responses, and induction of memory antibody responses. IgG anti-SRBC reduced the amount of SRBC in the spleens of wild-type, but not of FcγR-deficient mice. However, no correlation between suppression and the amount of SRBC in the spleen was observed, suggesting that increased clearance does not explain IgG-mediated suppression. Instead, we found compelling evidence for epitope masking because IgG anti-NP administered with NP-SRBC suppressed the IgG anti-NP, but not the IgG anti-SRBC response. Vice versa, IgG anti-SRBC administered with NP-SRBC, suppressed only the IgG anti-SRBC response. In conclusion, passively transferred IgG suppressed all measured parameters of an antigen-specific antibody/B cell response and an important mechanism of action is likely to be epitope masking.

Keywords: FcγR, complement, sheep erythrocytes, IgG-mediated immune suppression, rhesus prophylaxis, rhesus D antigen

Introduction

When antibodies are passively administered together with their specific antigen, they either down- or upregulate the antibody response against this antigen (13). IgM, IgG, and IgE enhance antibody responses and their effects depend on interactions of the immune complexes with Fc- or complement receptors, causing more efficient delivery of antigen to splenic B cell follicles and/or causing enhanced presentation of antigen to CD4+ T cells. Interestingly, IgG has a dual role and the same monoclonal IgG anti-2,4,6-trinitrophenyl that enhances carrier responses when administered with haptenated proteins, suppresses carrier responses when administered with haptenated erythrocytes (4, 5). Since the 1960s, the suppressive capacity of IgG has been used clinically to protect rhesus D antigen (RhD)-negative women from becoming immunized against fetal RhD-positive erythrocytes entering the maternal circulation through transplacental hemorrhage (6). Administration of IgG anti-RhD to these women has significantly reduced the frequency of hemolytic disease of the fetus and newborn (7). The mechanism behind the dramatic ability of IgG to suppress antibody responses has been elusive. It is of substantial theoretical interest to understand how small amounts of IgG can completely prevent antibody responses to the antigen they recognize. Understanding these mechanisms may also aid in finding effective monoclonal IgG anti-RhD antibodies to use in RhD-prophylaxis.

In the majority of previous studies of IgG-mediated suppression, the number of B cells producing sheep red blood cell (SRBC)-specific IgM during the first week after immunization was analyzed in mice immunized with native SRBC ± IgG anti-SRBC or haptenated SRBC ± IgG anti-hapten. Frequently, more than 99% of early IgM responses were suppressed (813). IgG suppresses also primary IgG responses (1416) and, when administered immediately prior to a secondary immunization, induction of a secondary antibody response (11). Whether IgG can suppress priming for a memory antibody response against SRBC is less clear. Some studies demonstrate that IgG-mediated suppression of priming does occur, although it is usually less efficient than suppression of a primary response (10, 14, 17, 18), while others find no suppression (19). IgG does not prevent priming of T helper cells (10, 15, 16).

The mechanism underlying IgG-mediated suppression has been intensely investigated over the years. Remarkably, no knockout mouse strain has been found in which suppression does not work. It operates well in mice lacking the activating Fc gamma receptors FcγRI, FcγRIII, and FcγRIV (FcRγ KO), the inhibitory FcγRIIB (FcγRIIB KO), the neonatal Fc receptor (FcRn) (β2-microglobulin KO) (10, 11, 20, 21), as well as complement factor C1q (C1q KO), complement factor C3 (C3 KO), or complement receptors 1 and 2 (CR1/2 KO) (21). Moreover, a monoclonal IgG1 antibody, which is unable to activate complement, suppresses to the same degree as a complement-activating IgG1 antibody (22). Therefore, it seems unlikely that IgG-mediated suppression is caused by complement-mediated lysis of SRBC. Because suppression is normal in FcγRIIB KO mice, it is also unlikely that IgG suppresses through central B-cell inhibition, where co-crosslinking of the negatively regulating immunoreceptor tyrosine-based inhibitory motif-containing FcγRIIB and the B cell receptor (BCR) induces inhibition of B cell signaling (23). Other mechanisms that could explain IgG-mediated suppression are that IgG increases clearance, without involving complement or Fc-receptors, or that IgG masks epitopes on the antigen, and prevents B cells from binding and becoming activated. Clearance and epitope masking are not mutually exclusive, and mathematical modeling has suggested that both are operative and can act synergistically (24). Passive administration of IgM of different affinities interferes with the development of germinal centers (GCs) and antibody production (25), but whether IgG regulates GC B cells has to our knowledge not been reported previously.

Here, the contribution of clearance and epitope masking has been studied in vivo using passively administered polyclonal SRBC- or 4-hydroxy-3-nitrophenyl acetyl (NP)-specific IgG antibodies as suppressors. The data strongly suggest that epitope masking plays a major role for suppression of IgG responses because only responses against the epitopes recognized by IgG were suppressed. No correlation was observed between IgG-mediated reduction of antigen in the spleen and suppression of the antibody response. In addition, we demonstrate for the first time that IgG suppresses the development of specific extrafollicular antibody-secreting cells, GC B cells as well as long-lived plasma cells. Finally, when primary antibody responses were suppressed to a very high degree (>96%), induction of immunological memory was suppressed to the same extent.

Materials and Methods

Mice

C57BL/6JBomTac mice (C57BL/6) were from Taconic Bioscience, Inc. (Hudson, NY, USA) and BALB/c mice from Bommice (Ry, Denmark). Fc receptor gamma chain (FcRγ) KO founders were a gift from Ravetch et al. (26) and were backcrossed to BALB/c for 10 generations. FcRγ KO mice lack the common FcRγ-chain and thereby all activating FcγRs associated with this chain (FcγRI, FcγRIII, and FcγRIV). Mice were age and sex matched within each experiment and were bred and maintained in the animal facilities of the National Veterinary Institute (Uppsala, Sweden). This study was carried out in accordance with the recommendations of the Uppsala Animal Research Ethics Committee and the protocol was approved by this committee.

Antibodies and Antigens Used for Immunizations

Polyclonal IgGa anti-SRBC and polyclonal IgGa anti-NP were prepared from hyperimmune BALB/c serum and polyclonal IgGb anti-SRBC from hyperimmune C57BL/6 serum. IgG was purified by affinity chromatography over a Protein-A Sepharose column (Amersham Pharmacia Biotech, Uppsala, Sweden) (27), dialyzed against PBS, sterile filtered and stored at −20°C until use. IgGa anti-NP was biotinylated using 0.18 mg EZ-Link Sulfo-NHS-LC-LC-Biotin (sulfosuccinimidyl-6-[biotinamido]-6-hexanamido hexaonate) (Thermo Scientific, Waltham, MA, USA) per 2 mg IgG according to manufacturer’s recommendations. The reaction was performed at room temperature for 30 min and free biotin was removed by dialysis against PBS. IgGa anti-NP-biotin was sterile filtered and stored at 4°C until use. SRBC were acquired from Håtunalab AB (Håtunaholm, Sweden) and stored in sterile Alsever’s solution at 4°C. SRBC were washed three times in PBS before use. 4-hydroxy-3-nitrophenylacetic-e-aminocaproyl-OSu (NP-ε-Aminocaproyl-OSu) (Biosearch Technologies, Petaluma, CA, USA) was conjugated to SRBC as described before (16). Briefly, NP-ε-Aminocaproyl-OSu was dissolved in dimethylformamide at a concentration of 7.5 mg/ml. Dissolved NP-ε-Aminocaproyl-OSu were then added to 5% SRBC suspensions in conjugation buffer (0.1 M NaHCO3 with 0.15 M NaCl, pH 8.5) to a final concentration of 250 μg/ml (in Figure Figure3,3, a final concentration of 1 mg/ml NP-ε-Aminocaproyl-OSu was used in order to achieve higher coupling ratio and facilitate visualization in sections) and incubated for 1 h at room temperature. After the conjugation reaction, cells were washed three times in PBS before use.

Figure 3Figure 3
IgG suppresses NP-specific extrafollicular antibody secreting cells and NP-specific germinal centers (GCs) B cells. C57BL/6 mice were immunized with 5 × 108 NP-sheep red blood cell (SRBC) ± 100 μg ...

Immunization and Blood Sampling

All mice were immunized with SRBC or NP-SRBC in one of their lateral tail veins in 200 μl PBS. Antigen-specific IgG was always administered in 200 μl PBS 30 min prior to antigen, also via the lateral tail veins. Controls received antigen alone or antigen-specific IgG alone. Secondary immunizations were done with SRBC alone. Further details of doses are given in the figure legends. The “default” doses were 30–50 μg IgG and 5 × 107 (NP-)SRBC, both of which are known cause 90–99% suppression of antibody responses to this amount of erythrocytes. In studies of NP-specific antibody-secreting cells (Figure (Figure3),3), the higher dose 5 × 108 NP-SRBC had to be used to induce detectable numbers of NP-specific cells and the dose of IgG was correspondingly increased to 100 μg. In immunological memory experiments, the lower priming dose 5 × 106 SRBC together with 10 μg IgG was used (Figure (Figure5A)5A) in addition to the default doses (Figure (Figure5B)5B) to test whether the strength of priming affected whether IgG was able to suppress memory induction or not. Blood was collected from the ventral tail artery.

Figure 5
IgG suppresses the induction of immunological memory. BALB/c mice were immunized with 5 × 106 sheep red blood cell (SRBC) ± 10 μg IgGb anti-SRBC+ or (A) or 5 × 10 ...

Enzyme-Linked Immunospot (ELISPOT)

Enzyme-linked immunospot assay was used for measuring SRBC-specific IgG-secreting cells (28). Briefly, 96-well plates (Costar 96-well enzyme immunoassay/RIA; Sigma-Aldrich, St. Louis, MO, USA) were coated with 0.25% SRBC. Spleen cells were diluted in cell culture medium (DMEM with 0.5% FCS), 100 μl was added to each well, and the plates were incubated at 37°C for 2.5 h. SRBC-specific antibodies produced by the single cells were detected after addition of goat anti-mouse IgG-alkaline phosphatase (Jackson ImmunoResearch Laboratories, Inc., West Baltimore Pike, Media, PA, USA) for 3 h at room temperature, followed by addition of the precipitating substrate 5-bromo-4-chloro-3-indolyl phosphate (Sigma-Aldrich) for 30 min at room temperature. The plates were washed three times in PBS and samples were counted blindly under a stereomicroscope.

Enzyme-Linked Immunosorbent Assay (ELISA)

Also NP- and SRBC-specific antibodies in sera were measured by ELISA (16). Briefly, 96-well plates (Costar 96-well enzyme immunoassay/RIA; Sigma-Aldrich) were coated with either 100 μl 0.25% SRBC or 100 μl NP20-BSA (Biosearch Technologies) (50 μg/ml) in PBS with 0.05% NaN3. The plates were then blocked with 5% dry milk at 4°C overnight. After washing three times with PBS, serum samples were serially diluted, added to the plates, and incubated overnight at 4°C. When measuring secondary IgG responses, starting serum dilution for titer determination was 1:5. Cutoff for titers was set as mean OD405nm + 2× SD for a group of eight individual sera from naive BALB/c mice diluted 1:5 (29). When measuring the IgG response, depending on the allotype of injected antibodies, either biotinylated anti-IgG1b (clone B68-2) and anti-IgG2ab (clone 5.7) or biotinylated anti-IgG1a (clone 10.9) and anti-IgG2aa (clone 8.3) (all from BD Pharmingen, San Jose, CA, USA) were mixed 1:1, added to each well, and incubated overnight at 4°C. After washing, alkaline phosphatase-conjugated streptavidin (BD Pharmingen, San Jose, CA, USA) was added and incubated for 3 h at room temperature. After washing, plates were developed using the substrate (p-nitrophenylphosphate; Sigma-Aldrich). Absorbance at 405 nm was measured and data analyzed using SoftMax software (Molecular Devices, Sunnyvale, CA, USA).

Flow Cytometry

Spleen cells were prepared as described before (30) and re-suspended in FACS buffer (PBS with 2% fetal bovine serum). Samples were treated with Fc block (anti-CD16/32; BD Biosciences, San Jose, CA, USA) for 10 min on ice, then stained with anti-B220-Alexa700 (clone RA3-6B2), anti-GL7-BV421 (clone GL7), anti-CD95-PEcy7 (clone Jo2), anti-λ1-biotin (clone R11-153) (all from BD Biosciences) at 4°C for 30 min. After washing twice in FACS buffer, samples were stained with streptavidin-FITC and NP-PE at 4°C for 30 min and re-suspended in 300 μl FACS buffer after washing in FACS buffer. For each sample, 2–3 million events were acquired on a LSR Fortessa cytometer (BD Biosciences) at the BioVis platform, SciLifeLab, Uppsala, Sweden. Data were analyzed with FlowJo software (Tree Star Inc., Ashland, OR, USA).

Confocal Laser Scanning Microscopy

Spleens were harvested, embedded in optimal cutting temperature embedding compound (VWR international, Radnor, PA, USA), flash-frozen in liquid nitrogen, and stored at −80°C. Eight-micrometer sections were cut using Thermo Scientific CryoStar NX70 Cryostat (Thermo Scientific, Waltham, MA, USA), thaw-mounted on frost plus microscope slides (Menzel-Gläser, Braunschweig, Germany), air-dried and stored at −80°C until use. Prior to staining, slides were fixed in 4% paraformaldehyde (Merck, Darmstadt, Germany) in PBS (pH 7.8) for 15 min or in 50% acetone for 30 s followed by 100% acetone (Sigma-Aldrich) for 5 min. Slides were then rehydrated in PBS and blocked with 5% horse serum (Sigma-Aldrich) in PBS for 30 min. Slides were stained with primary antibodies for 1 h. After washing twice in PBS, fluorochrome-conjugated streptavidin was added and the slides were incubated for 1 h and washed twice in PBS prior to mounting with Fluoromount G (Southern Biotech, Birmingham, AL, USA). For detection of NP-specific B cells, slides were stained with anti-IgD-Alexa 488 (clone 11-26C.2a, BioLegend, San Diego, CA, USA) and NP-PE (Biosearch Technologies). Localization of SRBC to splenic marginal zones (MZs) were investigated using anti-B220-Pacific blue (clone RA3-6B2, BD Biosciences), anti-CD169 (MOMA)-FITC (clone MOMA-1, AbD Serotec, Raleigh, NC, USA), and NP-SRBC detection by an in-house produced polyclonal IgG anti-NP-biotin followed by streptavidin-PE (eBioscience, San Diego, CA, USA). Images of immunofluorescence were acquired blindly and randomized with a LSM 700 confocal microscope (Carl Zeiss, Thornwood, NY, USA) using Zen 2009 software (Carl Zeiss). Tile-scan images of whole spleen sections were acquired using Zen 2009 software. Images were analyzed blindly with ImageJ software (NIH, Bethesda, MD, USA).

Statistical Analysis

Statistical differences between groups were determined by the two-tailed Student’s t-test. Statistical significance levels were set as: ns, p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001.

Results

IgG-Mediated Decrease of the Amount of SRBC in the Spleen Is Dependent on Activating FcγRs and Does Not Correlate with Suppression

Specific IgG administered together with SRBC reduces the localization of SRBC in the MZ of the spleen and increases clearance of SRBC from the blood (16). However, after 10 min, the levels of SRBC in the circulation were undetectable, regardless of whether IgG had been co-administered or not (16). The correlation between suppression and antigen localization was not directly assessed nor was the importance of FcγRs studied. To investigate this, BALB/c and FcRγ KO mice were immunized with IgG anti-SRBC + 5 × 107 NP-SRBC, 5 × 107 NP-SRBC alone, or with 1 × 107 NP-SRBC alone. Spleens were harvested after 10 min and the amount of extracellular NP-SRBC was determined by confocal laser scanning microscopy (Figures (Figures1A–R;1A–R; enhanced images are shown in Figure S1 in Supplementary Material). In parallel, the serum IgG anti-SRBC response was followed in groups of mice immunized at the same time (Figure (Figure1S).1S). Because the passively administered IgG was obtained from mice with a different IgG allotype than the recipient mice, the actively produced endogenous IgG antibodies could be distinguished by an allotype-specific ELISA (21). Administration of IgG significantly reduced the amount of SRBC in the MZ of wild-type BALB/c mice (Figures (Figures1B,F1B,F vs. Figures Figures1A,E;1A,E; Figure Figure1Q)1Q) as well as in the entire spleen section (Figure (Figure1R;1R; Figure S2 in Supplementary Material). BALB/c mice immunized with 1 × 107 NP-SRBC alone, or with the fivefold higher amount of NP-SRBC together with IgG anti-SRBC, had comparable amounts of NP-SRBC in their spleens (Figures (Figures1C,G,R).1C,G,R). In spite of this, mice immunized with 1 × 107 NP-SRBC alone mounted a potent antibody response while mice immunized with IgG anti-SRBC + 5 × 107 NP-SRBC had a suppressed antibody response (Figure (Figure1S).1S). Some spleens were also analyzed for NP-SRBC after 1 h and 24 h, but, as expected, very little or no antigen could be detected at these time points [Ref. (31) and data not shown]. In FcRγ KO mice, IgG was unable reduce the amount of SRBC in the MZ (Figures (Figures1J,N,Q)1J,N,Q) and in the entire spleen (Figure (Figure1R).1R). In spite of the similar amounts of SRBC in the spleens, the antibody response was suppressed in the IgG group (Figure (Figure11S).

Figure 1
IgG-mediated decrease of the amount of sheep red blood cell (SRBC) in the spleen is dependent on activating FcγRs and does not correlate with suppression. BALB/c and FcRγ KO mice were immunized with 5 × 107 NP-SRBC ± 50 μg ...

In summary, in BALB/c mice, equal (low) levels of antigen in the spleen can result in high (1 × 107 NP-SRBC-group) or suppressed (IgG + 5 × 107 NP-SRBC-group) antibody responses. In FcγR KO mice, equal (high) levels of antigen can result in high (5 × 107 NP-SRBC) or suppressed (IgG + 5 × 107 NP-SRBC-group) antibody responses. This lack of correlation between suppression and the amount of NP-SRBC detected in the spleen is hard to reconcile with clearance of antigen as the major explanation for IgG-mediated suppression. Moreover, the observations confirm that administration of SRBC-specific IgG reduces the amount of antigen localized in the spleen (16) and demonstrate that the reduction is dependent on activating FcγRs while the suppression of antibody responses is not.

Epitope-Specific Suppression of IgG Responses

Next, we sought to determine whether IgG only suppresses responses against the epitopes to which it binds (epitope-specific suppression) or whether it, in addition, suppresses responses against other epitopes on the same antigen (non-epitope specific suppression). To this end, C57BL/6 mice were immunized with NP-SRBC alone or together with either IgG anti-NP or IgG anti-SRBC. The mice were bled every 2 weeks and their antibody responses against NP and SRBC were analyzed. IgG anti-NP suppressed the NP- but not the SRBC-specific IgG-responses (Figures (Figures2A,B)2A,B) while IgG anti-SRBC suppressed the SRBC- but not the NP-specific IgG response (Figures (Figures2C,D).2C,D). These observations were highly reproducible (4/4 experiments with IgG anti-NP and 2/2 with IgG anti-SRBC) and demonstrate that IgG is able to suppress IgG responses in an epitope-specific way.

Figure 2
Epitope-specific suppression of IgG responses. C57BL/6 mice were immunized with 5 × 107 NP-sheep red blood cells (SRBC) ± 30 μg IgGa anti-NP or (A,B) with 5 × 107 ...

IgG Suppresses NP-Specific Extrafollicular Antibody-Secreting Cells and NP-Specific GC B Cells

In previous studies, the ability of IgG to suppress the overall serum antibody levels or splenic antibody-secreting cells was analyzed. Here, we investigated which B cell subpopulations were suppressed by IgG, using a system in which the BCRs of the antigen-specific B cells could be stained directly. The antibody response against NP in C57BL/6 mice is genetically restricted, mainly comprising λ1 light chains and the V186.2 segment of the VHJ558 gene family (32). Therefore, staining for λ1 and NP can be used to identify NP-specific B cells. C57BL/6 mice were immunized with NP-SRBC ± IgG anti-NP and negative controls with unconjugated SRBC or left unimmunized. Six days later, spleens were analyzed for NP-binding cells with flow cytometry and confocal microscopy (Figure (Figure3).3). In mice immunized with NP-SRBC alone, a small population of λ1+NP+B220+ cells were identified both among the GL7high CD95high GC B cells (Figure (Figure3B3B bottom right panel; Figure Figure3C)3C) and among the GL7lowCD95low non-GC B cells (Figure (Figure3B3B bottom left panel; Figure Figure3C).3C). The NP-specific cells (GC B cells and non-GC B cells together) constituted approximately 0.05% of the total B220+ population and ~1/5 were GC B cells and ~4/5 non-GC B cells (Figure (Figure3C).3C). Administration of IgG anti-NP together with NP-SRBC abolished the induction of NP-specific GC and non-GC B cells (Figures (Figures3A,C).3A,C). In fact, the levels in these mice were equally low as in mice immunized with unconjugated SRBC or left untreated (Figure (Figure33C).

The other half of the spleens were analyzed in confocal microscopy (Figures (Figures3D–I).3D–I). NP-binding cells were readily detected in extrafollicular foci in mice immunized with NP-SRBC (Figure (Figure3E)3E) while very few NP-binding cells were detected in mice immunized with IgG anti-NP + NP-SRBC (Figure (Figure3D)3D) and in the negative controls (Figures (Figures3F,G).3F,G). Although it cannot be excluded that some of the NP-binding cells in extrafollicular foci had exited GCs, the majority are presumably true extrafollicular cells owing to the early time point at which they were analyzed. Importantly, all NP-specific cells outside the follicles, regardless of their origin, are absent in mice immunized with IgG anti-NP + NP-SRBC. NP-specific cells could also be detected in some GCs (Figure (Figure3H).3H). GC B cells stained less brightly than the extrafollicular NP-specific cells possibly due to a wider span in affinity (33) and lower Ig expression. To confirm that the unstained areas close to the IgD+ areas are indeed GCs, co-staining with PNA was performed (Figure S3 in Supplementary Material). In summary, IgG anti-NP can suppress the generation of both extrafollicular NP-specific antibody-secreting cells and NP-specific GC B cells.

IgG Suppresses the Generation of Long-Lived Plasma Cells

To determine whether IgG suppressed the development of long-lived plasma cells, mice were immunized with SRBC ± IgG anti-SRBC and the number of SRBC-specific IgG-secreting cells in the spleen and bone marrow was analyzed 5–70 days after immunization (Figure (Figure4).4). Cells secreting IgG anti-SRBC were detected in both organs at all times, but were severely suppressed in the groups receiving IgG together with SRBC. As expected, the number of antibody-producing cells in the spleen was highest early after immunization and then decreased, while the cell number in the bone marrow increased during the entire time period. Thus, administration of IgG anti-SRBC efficiently suppressed the specific IgG-secreting cells at all times, both in spleen and bone marrow.

Figure 4
IgG suppresses the generation of long-lived plasma cells. BALB/c mice were immunized with 5 × 107 sheep red blood cell (SRBC) ± 30 μg IgGb anti-SRBC. Spleens and bone marrow were harvested ...

IgG Suppresses Induction of Immunological Memory

To test the ability of IgG to regulate memory induction, BALB/c mice were immunized in two regimes: 5 × 107 SRBC ± 50 μg IgG anti-SRBC or 5 × 106 SRBC ± 10 μg IgG anti-SRBC. The IgG anti-SRBC responses were followed during 63 days after priming, confirming efficient suppression (Figures (Figures5A,B).5A,B). And, 70 days after priming, all mice were boosted with a suboptimal number of SRBC and, in addition, a group of naive mice received the same “booster” dose. Because of the great differences in antibody levels between the groups, we analyzed the antibody responses as endpoint titers, starting at a serum dilution of 1:5. In mice that had been primed with SRBC alone and boosted, a very high secondary antibody response was observed (Figures (Figures5A,B).5A,B). In mice primed with IgG + SRBC and boosted, secondary responses were low (Figures (Figures5A,B).5A,B). A minute priming effect was, however, visible also in the IgG groups, evidenced by the fact that their antibody titers were higher than those in naive and “boosted” mice (Figures (Figures5A,B).5A,B). Naive mice, primed on day 70 with the suboptimal dose 5 × 105 SRBC, produce low titers of IgG antibodies [mean titers: 30 (Figure (Figure5A)5A) and 1,100 (Figure (Figure5B)],5B)], which are barely visible in the figures. The relative suppression of primary responses and induction of memory appeared to be equal. In the low dose experiment, IgG suppressed 96% of the IgG-response on day 21 and 99% on day 91 (21 days after boost) (Figure (Figure5A).5A). In the high dose experiment, suppression was 97% both 21 days after priming and 21 days after boost (Figure (Figure5B).5B). Thus, when IgG-mediated suppression of primary antibody responses is very efficient, priming for secondary antibody responses seems to follow along the same lines.

Discussion

Generation of an adaptive antibody response is a complicated process, and one purpose of the present investigation was to define in detail which parameters along this line that can be suppressed by IgG. After the initial interaction between antigen, B cells, and cognate T cells, the specific B cells can differentiate into extrafollicular short-lived IgM- or IgG-secreting cells, or GC-independent memory B cells. Other B cells enter the GC pathway, go through hypermutation followed by selection for high affinity and class switch recombination becoming either GC-dependent memory B cells or long-lived plasma cells [reviewed in Ref. (3436)]. Differentiation between IgG-mediated suppression of extrafollicular B cells, non-GC B cells, and GC B cells in the spleen is not possible by just looking at serum antibodies or direct plaque-forming cell assay. In order to detect single antigen-specific B cells in vivo, usually Ig-transgenic mice immunized with antigen in adjuvants are used. Here, we managed to set up a system in which i.v. immunization of C57BL/6 mice with 5 × 108 NP-SRBC in PBS resulted in NP-specific B cell populations, which were detectable through staining of specific BCR with NP-PE. Administration of IgG anti-NP completely prevented development of NP-specific extrafollicular B cells, non-GC B cells, and GC B cells (Figure (Figure3).3). IgG anti-SRBC also suppressed the development of long-lived plasma cells in bone marrow obtained up to 70 days after immunization (Figure (Figure44).

An important function of the adaptive immune system is the generation of long-lived memory B cells. Whether IgG, acting to suppress a primary response, also inhibits priming for immunological memory has not been unequivocally determined (10, 14, 1719). By using an ELISA that discriminates between passively administered and actively produced, endogenous IgG, and by measuring the IgG levels in the serum as endpoint titers, we could directly compare the relative suppression of primary and secondary IgG responses. The data show that when primary responses were suppressed by 96% or more, secondary responses were also suppressed by 96% or more. Thus, the relative suppression of a primary IgG response and priming for a secondary IgG response is very similar (Figure (Figure5).5). This is in accordance with current knowledge about the development of memory B cells, most of which are generated during the first weeks of an immunization (36). Therefore, it would be expected that lack of B cell stimulation, owing to IgG-mediated inhibition of the interaction between antigen and B cells, during this time, would result in lack of memory B cells. When the primary B cell response is only partially suppressed, a partial suppression of priming would be the logical result, and this may explain why priming has sometimes been found to be only moderately suppressed. The observation is also consistent with the successful RhD prophylaxis in humans in which administration of IgG anti-RhD to women at the first pregnancy with a RhD-positive baby protects against immunization during the next pregnancy (6, 7).

To further elucidate the mechanism underlying IgG-mediated suppression, we focused on differentiating between the two hypotheses that are currently mainly discussed, antigen clearance and epitope masking. Provided FcγRs were expressed in the mice, IgG was able to increase clearance, but no correlation between the antibody response and the amount of NP-SRBC found in the spleens was observed (Figure (Figure1).1). These findings are consistent with previous observations. IgG administered several days after SRBC causes suppression (11, 12, 3740) in spite of the fact that SRBC is cleared from the circulation of mice within 10 min of immunization (16). In a model using as antigen transgenic mouse erythrocytes (HOD-RBC), which express hen egg lysozyme in tandem sequence with T cell determinants of ovalbumin (OVA) and the complete human Duffyb transmembrane protein (41), a panel of monoclonal IgG antibodies were tested for ability to suppress the OVA-specific antibody response. Three of the antibodies induced clearance while three did not, but all six were efficient suppressors (42). In addition, monoclonal anti-RhD administered together with RhD+ erythrocytes to RhD subjects induced rapid clearance of erythrocytes but failed to suppress the antibody response (43, 44).

Direct evidence for a role of epitope masking in IgG-mediated suppression is difficult to obtain, and this hypothesis will probably remain a “diagnosis by exclusion.” Epitope masking by IgM antibodies was, however, suggested to play an important role in selection of B cells in germinal centers (25), and to be the most important explanation for poor secondary antibody responses to the stem of the influenza surface hemagglutinin during vaccinations (45). The highly reproducible epitope specificity of suppression of the IgG responses shown in Figure Figure22 lends strong support for the epitope masking hypothesis. This finding may be the closest to a direct proof for the epitope masking hypothesis, which is possible to obtain. Importantly, epitope specificity of suppression has been reported previously (12, 46). However, also non-epitope specific suppression has been observed, mainly in systems studying IgM-producing single B cells during the first week of immunization (4, 9, 10, 13, 16, 22, 42). Because non-epitope specificity has been interpreted as evidence for Fc-dependence of suppression and, therefore, to argue against the epitope masking mechanism, this is an important issue. The existence of non-epitope specific suppression needs to be accommodated with the increasing support for Fc-independence of suppression obtained from studies of FcγR- and complement-deficient mice (10, 11, 2022) and the observations that F(ab′)2 fragments can suppress (10, 20, 47, 48). We have suggested (10, 49), and still believe, that the best explanation for the apparent paradox of lack of Fc-dependence and existence of non-epitope specific suppression is steric hindrance. IgG binding to an epitope present at high density prevents B cells from binding to the specific epitope (via epitope masking) as well as to neighboring non-specific epitopes (via steric hindrance). When IgG binds to an epitope present at low density, it would only prevent B cells from binding to the specific epitope. Thus, in conditions with high epitope density, non-epitope specific suppression will be observed and in conditions with low epitope density, epitope-specific suppression will take place. With this reasoning, both epitope-specific and non-epitope-specific suppression can be understood, although suppression is independent of the IgG(Fc) part. Experimental support for this idea comes from studies where hapten-specific IgG antibodies suppressed non-epitope-specific SRBC-responses when administered together with high hapten-density SRBC, but not with low hapten-density SRBC (5, 16). In analogy, the amount of IgG that binds to SRBC correlates with how efficiently suppression is induced (9, 50), mixtures of passively administered different monoclonal IgG antibodies induce more efficient suppression than administration of saturating doses of each IgG antibody alone (9, 51, 52), and high affinity of IgG promotes efficient suppression (13, 53). In humans, a strong argument against the epitope masking mechanism has been a study in which anti-Kell antibodies could suppress responses against RhD epitopes (54). However, it was recently shown that the RhD and Kell antigens are positioned closely together on human erythrocytes (55) and, therefore, these observations may perhaps be explained by epitope masking in combination with steric hindrance.

Compatible with epitope masking is also the lack of correlation between clearance and suppression, discussed above, and the fact that T cells are not suppressed by IgG (10, 15, 16). This is what would be expected because epitope masking would not prevent antigen from being internalized and processed by the APCs, which subsequently activate CD4+ T cells. Obviously, some experimental data are not compatible with the epitope masking hypothesis. For example, F(ab′)2 fragments have been reported to be unable to suppress (4, 13, 17). This can possibly be explained by increased elimination of these fragments owing to lack of binding to FcRn (56), but this issue needs further experimentation. Another argument against epitope masking comes from the HOD-RBC model, in which a monoclonal IgG anti-Duffy antibody was able to non-epitope specifically suppress anti-HEL responses although it did not sterically block binding of serum IgM anti-HEL to HOD-RBC (42). However, it remains to be elucidated how well competition with serum IgM resembles the in vivo situation where B cells themselves compete with the suppressive IgG.

In addition to the use of suppressive IgG in RhD prophylaxis, an important clinical issue is the negative impact of passively transferred pathogen-specific maternal antibodies on vaccination of infants [reviewed in Ref. (5759)]. Also within this field, the mechanisms discussed are FcγRIIB-mediated inhibition, clearance, and epitope masking, but so far, no concensus has been reached.

In summary, the current study extends our understanding of IgG-mediated suppression in two principal ways. First, it suggests that IgG administered in close temporal relationship to antigen inhibits all pathways of B cell differentiation. Serum IgG as well as extrafollicular B cells, non-GC B cells, GC B cells, long-lived plasma cells, and memory B cells are all suppressed. Second, it provides strong evidence for the importance of epitope masking and suggests that the role of IgG-mediated antigen clearance is negligible.

Author Contributions

JB and HX: designed and performed experiments, and wrote the manuscript. BH: designed experiments and wrote the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

We thank Annika Westin for skillful technical assistance. This work was supported by Uppsala University, The Swedish Research Council, China Scholarship Council, Ellen, Walter, and Lennart Hesselman’s Foundation, Hans von Kantzow’s Foundation, King Gustaf V:s 80 Years Foundation, Ollie and Elof Ericsson’s Foundation, and Agnes and Mac Rudberg’s Foundation. The flow cytometric analyses were performed on instruments provided by the SciLifeLab BioVis platform at Uppsala University.

Supplementary Material

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fimmu.2017.00238/full#supplementary-material.

Abbreviations

BCR, B cell receptor; C1q, complement factor 1q; C3, complement factor 3; ELISPOT, enzyme-linked immunospot assay; ELISA, enzyme-linked immunosorbent assay; FcγR, Fc gamma receptor; FcRγ, Fc receptor gamma chain; FcRn, the neonatal Fc receptor; GC, germinal center; HEL, hen egg lysozyme; HOD, HEL-OVA-duffy tandem protein; ITIM, immunoreceptor tyrosine-based inhibitory motif; MZ, marginal zone; NP, 4-hydroxy-3-nitrophenyl acetyl; OVA, ovalbumin; PFC, plaque-forming cell assay; RhD, rhesus D antigen; SRBCs, sheep red blood cells; TNP, 2,4,6-trinitrophenyl.

References

1. Heyman B.. Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu Rev Immunol (2000) 18:709–37.10.1146/annurev.immunol.18.1.709 [PubMed] [Cross Ref]
2. Heyman B.. Antibodies as natural adjuvants. Curr Top Microbiol Immunol (2014) 382:201–19.10.1007/978-3-319-07911-0_9 [PubMed] [Cross Ref]
3. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev (2010) 236:265–75.10.1111/j.1600-065X.2010.00910.x [PubMed] [Cross Ref]
4. Enriquez-Rincon F, Klaus GG.. Differing effects of monoclonal anti-hapten antibodies on humoral responses to soluble or particulate antigens. Immunology (1984) 52:129–36. [PubMed]
5. Wiersma EJ, Coulie PG, Heyman B.. Dual immunoregulatory effects of monoclonal IgG-antibodies: suppression and enhancement of the antibody response. Scand J Immunol (1989) 29:439–48.10.1111/j.1365-3083.1989.tb01143.x [PubMed] [Cross Ref]
6. Clarke CA, Donohoe WTA, Woodrow JC, Finn R, Krevans JR, Kulke W, et al. Further experimental studies on the prevention of Rh haemolytic disease. Br Med J (1963) 1:979–84.10.1136/bmj.1.5336.979 [PMC free article] [PubMed] [Cross Ref]
7. Urbaniak SJ, Greiss MA.. RhD haemolytic disease of the fetus and the newborn. Blood Rev (2000) 14:44–61.10.1054/blre.1999.0123 [PubMed] [Cross Ref]
8. Henry C, Jerne N.. Competition of 19S and 7S antigen receptors in the regulation of the primary immune response. J Exp Med (1968) 128:133–52.10.1084/jem.128.1.133 [PMC free article] [PubMed] [Cross Ref]
9. Heyman B, Wigzell H.. Immunoregulation by monoclonal sheep erythrocyte-specific IgG antibodies: suppression is correlated to level of antigen binding and not to isotype. J Immunol (1984) 132:1136–43. [PubMed]
10. Karlsson MC, Wernersson S, Diaz de Stahl T, Gustavsson S, Heyman B.. Efficient IgG-mediated suppression of primary antibody responses in Fcgamma receptor-deficient mice. Proc Natl Acad Sci U S A (1999) 96:2244–9.10.1073/pnas.96.5.2244 [PubMed] [Cross Ref]
11. Karlsson MC, Getahun A, Heyman B.. FcgammaRIIB in IgG-mediated suppression of antibody responses: different impact in vivo and in vitro. J Immunol (2001) 167:5558–64.10.4049/jimmunol.167.10.5558 [PubMed] [Cross Ref]
12. Möller G.. Antibody-mediated suppression of the immune response is determinant specific. Eur J Immunol (1985) 15:409–12.10.1002/eji.1830150420 [PubMed] [Cross Ref]
13. Brüggemann M, Rajewsky K. Regulation of the antibody response against hapten-coupled erythrocytes by monoclonal anti-hapten antibodies of various isotypes. Cell Immunol (1982) 71:365–73.10.1016/0008-8749(82)90270-2 [PubMed] [Cross Ref]
14. Heyman B, Wigzell H.. Specific IgM enhances and IgG inhibits the induction of immunological memory in mice. Scand J Immunol (1985) 21:255–66.10.1111/j.1365-3083.1985.tb01428.x [PubMed] [Cross Ref]
15. Brinc D, Le-Tien H, Crow AR, Freedman J, Lazarus AH.. IgG-mediated immunosuppression is not dependent on erythrocyte clearance or immunological evasion: implications for the mechanism of action of anti-D in the prevention of haemolytic disease of the newborn? Br J Haematol (2007) 139:275–9.10.1111/j.1365-2141.2007.06764.x [PubMed] [Cross Ref]
16. Getahun A, Heyman B.. Studies on the mechanism by which antigen-specific IgG suppresses primary antibody responses: evidence for epitope masking and decreased localization of antigen in the spleen. Scand J Immunol (2009) 70:277–87.10.1111/j.1365-3083.2009.02298.x [PubMed] [Cross Ref]
17. Nicholas R, Sinclair SC. Regulation of the immune response. I. Reduction in ability of specific antibody to inhibit longlasting IgG immunological priming after removal of the Fc fragment. J Exp Med (1969) 129:1183–201.10.1084/jem.129.6.1183 [PMC free article] [PubMed] [Cross Ref]
18. Safford JW, Jr, Tokuda S. Antibody-mediated suppression of the immune response: effect on the development of immunologic memory. J Immunol (1971) 107:1213–25. [PubMed]
19. Brinc D, Le-Tien H, Crow AR, Siragam V, Freedman J, Lazarus AH.. Immunoglobulin G-mediated regulation of the murine immune response to transfused red blood cells occurs in the absence of active immune suppression: implications for the mechanism of action of anti-D in the prevention of haemolytic disease of the fetus and newborn? Immunology (2008) 124:141–6.10.1111/j.1365-2567.2008.02807.x [PubMed] [Cross Ref]
20. Bernardo L, Yu H, Amash A, Zimring JC, Lazarus AH. IgG-mediated immune suppression to erythrocytes by polyclonal antibodies can occur in the absence of activating or inhibitory Fc-gamma receptors in a full mouse model. J Immunol (2015) 195:2224–30.10.4049/jimmunol.1500790 [PubMed] [Cross Ref]
21. Bergström JJ, Heyman B.. IgG suppresses antibody responses in mice lacking C1q, C3, complement receptors 1 and 2, or IgG Fc-receptors. PLoS One (2015) 10:e0143841.10.1371/journal.pone.0143841 [PMC free article] [PubMed] [Cross Ref]
22. Heyman B, Wiersma E, Nose M. Complement activation is not required for IgG-mediated suppression of the antibody response. Eur J Immunol (1988) 18:1739–43.10.1002/eji.1830181113 [PubMed] [Cross Ref]
23. Daëron M, Lesourne R.. Negative signaling in Fc receptor complexes. Adv Immunol (2006) 89:39–86.10.1016/S0065-2776(05)89002-9 [PubMed] [Cross Ref]
24. Na D, Kim D, Lee D. Mathematical modeling of humoral immune response suppression by passively administered antibodies in mice. J Theor Biol (2006) 241:830–51.10.1016/j.jtbi.2006.01.019 [PubMed] [Cross Ref]
25. Zhang Y, Meyer-Hermann M, George LA, Figge MT, Khan M, Goodall M, et al. Germinal center B cells govern their own fate via antibody feedback. J Exp Med (2013) 210(3):457–64.10.1084/jem.20120150 [PMC free article] [PubMed] [Cross Ref]
26. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcRg chain deletion results in pleiotrophic effector cell defects. Cell (1994) 76:519–29.10.1016/0092-8674(94)90115-5 [PubMed] [Cross Ref]
27. Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry (1978) 15:429.10.1016/0161-5890(78)90070-6 [PubMed] [Cross Ref]
28. Heyman B, Brogren I, Klareskog L. Comparison between the sensitivity of the hemolytic plaque forming cell assay and the enzyme linked immunospot assay in detecting B-cells producing trinitrophenyl- or sheep erythrocyte specific IgM- and IgG antibodies. J Immunol Methods (1991) 139:293–6.10.1016/0022-1759(91)90200-Y [PubMed] [Cross Ref]
29. Frey A, Di Canzio J, Zurakowski D.. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods (1998) 221:35–41.10.1016/S0022-1759(98)00170-7 [PubMed] [Cross Ref]
30. Henningsson F, Ding Z, Dahlin JS, Linkevicius M, Carlsson F, Grönvik KO, et al. IgE-mediated enhancement of CD4+ T cell responses in mice requires antigen presentation by CD11c+ cells and not by B cells. PLoS One (2011) 6:e21760.10.1371/journal.pone.0021760 [PMC free article] [PubMed] [Cross Ref]
31. Stamm C, Barthelmann J, Kunz N, Toellner KM, Westermann J, Kalies K.. Dose-dependent induction of murine Th1/Th2 responses to sheep red blood cells occurs in two steps: antigen presentation during second encounter is decisive. PLoS One (2013) 8:e67746.10.1371/journal.pone.0067746 [PMC free article] [PubMed] [Cross Ref]
32. Jacob J, Kelsoe G, Rajewsky K, Weiss U.. Intraclonal generation of antibody mutants in germinal centres. Nature (1991) 354:389–92.10.1038/354389a0 [PubMed] [Cross Ref]
33. Kuraoka M, Schmidt AG, Nojima T, Feng F, Watanabe A, Kitamura D, et al. Complex antigens drive permissive clonal selection in germinal centers. Immunity (2016) 44:542–52.10.1016/j.immuni.2016.02.010 [PMC free article] [PubMed] [Cross Ref]
34. Goodnow CC, Vinuesa CG, Randall KL, Mackay F, Brink R.. Control systems and decision making for antibody production. Nat Immunol (2010) 11:681–8.10.1038/ni.1900 [PubMed] [Cross Ref]
35. Mesin L, Ersching J, Victora GD.. Germinal center B cell dynamics. Immunity (2016) 45:471–82.10.1016/j.immuni.2016.09.001 [PMC free article] [PubMed] [Cross Ref]
36. Weisel FJ, Zuccarino-Catania GV, Chikina M, Shlomchik MJ.. A temporal switch in the germinal center determines differential output of memory B and plasma cells. Immunity (2016) 44:116–30.10.1016/j.immuni.2015.12.004 [PMC free article] [PubMed] [Cross Ref]
37. Finkelstein MS, Uhr JW.. Specific inhibition of antibody formation by passively administered 19S and 7S antibody. Science (1964) 146:67–9.10.1126/science.146.3640.67 [PubMed] [Cross Ref]
38. Wigzell H.. Antibody synthesis at the cellular level. Antibody-induced suppression of 7S antibody synthesis. J Exp Med (1966) 124:953–69.10.1084/jem.124.5.953 [PMC free article] [PubMed] [Cross Ref]
39. Chan PL, Sinclair NR. Regulation of the immune response. VI. Inability of F(ab')2 antibody to terminate established immune responses and its ability to interfere with IgG antibody-mediated immunosuppression. Immunology (1973) 24:289–310. [PubMed]
40. Heyman B.. Non-determinant specificity of feedback immunosuppression by IgG antibodies injected after the antigen. Scand J Immunol (1988) 27:361–5.10.1111/j.1365-3083.1988.tb02358.x [PubMed] [Cross Ref]
41. Desmarets M, Cadwell CM, Peterson KR, Neades R, Zimring JC.. Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model. Blood (2009) 114:2315–22.10.1182/blood-2009-04-214387 [PubMed] [Cross Ref]
42. Yu H, Stowell SR, Bernardo L, Hendrickson JE, Zimring JC, Amash A, et al. Antibody-mediated immune suppression of erythrocyte alloimmunization can occur independently from red cell clearance or epitope masking in a murine model. J Immunol (2014) 193:2902–10.10.4049/jimmunol.1302287 [PubMed] [Cross Ref]
43. Beliard R.. Monoclonal anti-D antibodies to prevent alloimmunization: lessons from clinical trials. Transfus Clin Biol (2006) 13:58–64.10.1016/j.tracli.2006.03.013 [PubMed] [Cross Ref]
44. Kumpel BM.. Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn. Clin Exp Immunol (2008) 154:1–5.10.1111/j.1365-2249.2008.03735.x [PubMed] [Cross Ref]
45. Zarnitsyna VI, Lavine J, Ellebedy A, Ahmed R, Antia R.. Multi-epitope models explain how pre-existing antibodies affect the generation of broadly protective responses to influenza. PLoS Pathog (2016) 12:e1005692.10.1371/journal.ppat.1005692 [PMC free article] [PubMed] [Cross Ref]
46. Brody NI, Walker JG, Siskind GW. Studies on the control of antibody synthesis. Interaction of antigenic competition and suppression of antibody formation by passive antibody on the immune response. J Exp Med (1967) 126:81–91.10.1084/jem.126.1.81 [PMC free article] [PubMed] [Cross Ref]
47. Tao TW, Uhr JW. Capacity of pepsin-digested antibody to inhibit antibody formation. Nature (1966) 212:208–9.10.1038/212208a0 [PubMed] [Cross Ref]
48. Cerottini JC, McConahey PJ, Dixon FJ. The immunosuppressive effect of passively administered antibody IgG fragments. J Immunol (1969) 102:1008–15. [PubMed]
49. Heyman B.. Antibody feedback suppression: towards a unifying concept? Immunol Lett (1999) 68:41–5.10.1016/S0165-2478(99)00028-0 [PubMed] [Cross Ref]
50. Heyman B, Pilström L. Primary and secondary IgG antibodies are equally efficient immunosuppressors in relation to antigen binding capacity. Immunol Lett (1988) 17:189–94.10.1016/0165-2478(88)90090-9 [PubMed] [Cross Ref]
51. Quintana IZ, Silveira AV, Moller G.. Regulation of the antibody response to sheep erythrocytes by monoclonal IgG antibodies. Eur J Immunol (1987) 17:1343–9.10.1002/eji.1830170919 [PubMed] [Cross Ref]
52. Bernardo L, Amash A, Marjoram D, Lazarus AH. Antibody-mediated immune suppression is effective when blends of anti-RBC monoclonal antibodies are used in mice. Blood (2016) 128:1076–80.10.1182/blood-2016-01-692178 [PubMed] [Cross Ref]
53. Walker JG, Siskind GW. Studies on the control of antibody synthesis. Effect of antibody affinity upon its ability to suppress antibody formation. Immunology (1968) 14:21–8. [PubMed]
54. Woodrow JC, Clarke CA, Donohow WT, Finn R, McConnell RB, Sheppard PM, et al. Mechanism of Rh prophylaxis: an experimental study on specificity of immunosuppression. Br Med J (1975) 2:57–9.10.1136/bmj.2.5962.57 [PMC free article] [PubMed] [Cross Ref]
55. Gauthier E, Guo X, Mohandas N, An X.. Phosphorylation-dependent perturbations of the 4.1R-associated multiprotein complex of the erythrocyte membrane. Biochemistry (2011) 50:4561–7.10.1021/bi200154g [PMC free article] [PubMed] [Cross Ref]
56. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta-2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A (1996) 93:5512–6.10.1073/pnas.93.11.5512 [PubMed] [Cross Ref]
57. Siegrist CA.. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine (2003) 21:3406–12.10.1016/S0264-410X(03)00342-6 [PubMed] [Cross Ref]
58. Niewiesk S.. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol (2014) 5:446.10.3389/fimmu.2014.00446 [PMC free article] [PubMed] [Cross Ref]
59. Edwards KM. Maternal antibodies and infant immune responses to vaccines. Vaccine (2015) 33:6469–72.10.1016/j.vaccine.2015.07.085 [PubMed] [Cross Ref]

Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA